• is an online educational resource on the genetics of cystic fibrosis (CF) and the role of CF transmembrane conductance regulator (CFTR) in normal human physiology as well as in CF.
  • The information contained herein is intended for healthcare professionals working within the European Union (EU).
  • The content of this website has been developed independently by a group of CF healthcare professionals and is for general information purposes only.
  • All of the information about CFTR and CFTR modulators has been obtained from referenced sources and is in the public domain.
  • This website is not intended to promote or advocate a particular course of treatment or any specific drug, whether licensed or unlicensed, nor is it intended to imply or suggest that any drug be used for any purpose other than that which for which it is licensed in the EU.


  • While we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information and related graphics, or products and treatments, contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
  • In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from, or in connection with, the use of this website.
  • Through this website you are able to link to other websites which are not under our control. We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
  • Every effort is made to keep the website up and running smoothly. However, we take no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.

Please see the full Terms & Conditions before using this website.


I have read and understood the above

Drug & research development » Clinical trials » NCT01614457

Study of Ivacaftor in Subjects With Cystic Fibrosis (CF) Who Have the R117H-CF Transmembrane Conductance Regulator (CFTR) Mutation (KONDUCT)

Official title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Who Have the R117H-CFTR Mutation

Clinical Trials gov number: NCT01614457

Click on the tabs to move through the sequence.

Purpose: To evaluate the efficacy and safety of ivacaftor in CF patients who have the R117H-CFTR mutation.

Phase: 3

Type: Interventional, randomized, double-blind, parallel assignment

Study sponsor: Vertex Pharmaceuticals Incorporated; Cystic Fibrosis Foundation Therapeutics

  • Male or female with confirmed diagnosis of CF
  • ≥1 allele of the R117H CFTR mutation
  • Percent predicted forced expiratory volume in 1 second (FEV1) 40–90% (for subjects aged ≥12 years) or 40–105% (for subjects aged 6–11 years) predicted normal for age, sex, and height
  • Minimum weight of 15kg at screening
  • Females of childbearing potential must not be pregnant
  • Willing to comply with contraception requirements


Geographical Location
United Kingdom, United States

Number of Participants
51-100 (≥6 years)

Primary Endpoint

Absolute change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) through Week 24

Secondary Endpoint

Time to first pulmonary exacerbation (Day 0-15, Day 57-112, Day 113-168)

At Week 24

  • Change from baseline (BL) in body mass index
  • Change from BL in sweat chloride
  • Change from BL in Cystic Fibrosis Questionnaire-Revised Respiratory Domain Score
  • Number of subjects with adverse events and serious adverse events  from baseline to 3-4 weeks after last dose at Week 24

Click on the tabs to move through the sequence.

  • Experimental:

     Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.

  • Placebo Comparator: Placebo

     Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.

View Trial Results